- Home
- JLL vs INCY Comparison
JLL vs INCY Comparison
Compare JLL & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLL | INCY |
|---|---|---|
| Founded | 1997 | 1991 |
| Country | United States | United States |
| Employees | 48000 | N/A |
| Industry | Real Estate | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8B | 17.0B |
| IPO Year | 1997 | 1994 |
Fundamental Metrics
Financial Performance| Metric | JLL | INCY |
|---|---|---|
| Price | $292.10 | $90.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 21 |
| Target Price | ★ $363.17 | $102.00 |
| AVG Volume (30 Days) | 425.7K | ★ 1.4M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 45.13 | ★ 4173.33 |
| EPS | ★ 16.40 | 6.41 |
| Revenue | ★ $26,115,600,000.00 | $3,394,635,000.00 |
| Revenue This Year | $7.70 | $10.97 |
| Revenue Next Year | $6.91 | $10.48 |
| P/E Ratio | $18.28 | ★ $14.40 |
| Revenue Growth | 11.45 | ★ 13.67 |
| 52 Week Low | $194.36 | $53.56 |
| 52 Week High | $363.06 | $112.29 |
Technical Indicators
Market Signals| Indicator | JLL | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 35.21 |
| Support Level | $279.24 | $82.66 |
| Resistance Level | $309.79 | $92.86 |
| Average True Range (ATR) | 9.46 | 2.28 |
| MACD | 0.74 | -0.05 |
| Stochastic Oscillator | 36.74 | 13.12 |
Price Performance
Historical ComparisonAbout JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.